Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
QJM ; 108(3): 219-29, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25223570

ABSTRACT

BACKGROUND: Infective endocarditis (IE) causes substantial morbidity and mortality. Patient and pathogen profiles, as well as microbiological and operative strategies, continue to evolve. The impact of these changes requires evaluation to inform optimum management and identify individuals at high risk of early mortality. AIM: Identification of clinical and microbiological features, and surgical outcomes, among patients presenting to a UK tertiary cardiothoracic centre for surgical management of IE between 1998 and 2010. DESIGN: Retrospective observational cohort study. METHODS: Clinical, biochemical, microbiological and echocardiographic data were identified from clinical records. Principal outcomes were all-cause 28-day mortality and duration of post-operative admission. RESULTS: Patients (n = 336) were predominantly male (75.0%); median age 52 years (IQR = 41-67). Most cases involved the aortic (56.0%) or mitral (53.9%) valves. Microbiological diagnoses, obtained in 288 (85.7%) patients, included streptococci (45.2%); staphylococci (34.5%); Haemophilus, Actinobacillus, Cardiobacterium, Eikenella, Kingella (HACEK) organisms (3.0%); and fungi (1.8%); 11.3% had polymicrobial infection. Valve replacement in 308 (91.7%) patients included mechanical prostheses (69.8%), xenografts (24.0%) and homografts (6.2%). Early mortality was 12.2%, but fell progressively during the study (P = 0.02), as did median duration of post-operative admission (33.5 to 10.5 days; P = 0.0003). Multivariable analysis showed previous cardiothoracic surgery (OR = 3.85, P = 0.03), neutrophil count (OR = 2.27, P = 0.05), albumin (OR = 0.94, P = 0.04) and urea (OR = 2.63, P < 0.001) predicted early mortality. CONCLUSIONS: This study demonstrates reduced post-operative early mortality and duration of hospital admission for IE patients over the past 13 years. Biomarkers (previous cardiothoracic surgery, neutrophil count, albumin and urea), predictive of early post-operative mortality, require prospective evaluation to refine algorithms, further improve outcomes and reduce healthcare costs associated with IE.


Subject(s)
Endocarditis, Bacterial/surgery , Gram-Negative Bacterial Infections/surgery , Gram-Positive Bacterial Infections/surgery , Heart Valve Diseases/surgery , Mycoses/surgery , Adult , Aged , Echocardiography , Endocarditis, Bacterial/microbiology , Endocarditis, Bacterial/mortality , Female , Gram-Negative Bacterial Infections/microbiology , Gram-Negative Bacterial Infections/mortality , Gram-Positive Bacterial Infections/microbiology , Gram-Positive Bacterial Infections/mortality , Heart Valve Diseases/microbiology , Heart Valve Diseases/mortality , Heart Valve Prosthesis Implantation/statistics & numerical data , Humans , Length of Stay/statistics & numerical data , Male , Middle Aged , Mycoses/microbiology , Mycoses/mortality , Patient Readmission/statistics & numerical data , Retrospective Studies , Risk Factors , Substance Abuse, Intravenous/complications , Treatment Outcome
3.
J Hosp Infect ; 62(1): 6-21, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16310890

ABSTRACT

The increase since the mid 1980s in glycopeptide resistant enterococci (GRE) raised concerns about the limited options for antimicrobial therapy, the implications for ever-increasing numbers of immunocompromised hospitalised patients, and fuelled fears, now realised, for the transfer of glycopeptide resistance to more pathogenic bacteria, such as Staphylococcus aureus. These issues underlined the need for guidelines for the emergence and control of GRE in the hospital setting. This Hospital Infection Society (HIS) and Infection Control Nurses Association (ICNA) working party report reviews the literature relating to GRE prevention and control. It provides guidance on microbiological investigation, treatment and management, including antimicrobial prescribing and infection control measures. Evidence identified to support recommendations has been categorized. A risk assessment approach is recommended and areas for research and development identified.


Subject(s)
Anti-Bacterial Agents/pharmacology , Cross Infection/prevention & control , Drug Resistance, Bacterial , Enterococcus/drug effects , Glycopeptides/pharmacology , Gram-Positive Bacterial Infections/prevention & control , Hospitals , Anti-Bacterial Agents/therapeutic use , Cross Infection/epidemiology , Cross Infection/microbiology , Enterococcus/classification , Enterococcus/isolation & purification , Gram-Positive Bacterial Infections/epidemiology , Gram-Positive Bacterial Infections/microbiology , Humans , Infection Control/methods , Vancomycin Resistance
4.
J Hosp Infect ; 49(3): 183-92, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11716635

ABSTRACT

Two aminoglycoside-resistant strains of Klebsiella pneumoniae caused an outbreak on the neonatal unit at St Thomas' Hospital. One, which affected 18 patients, was capsular type K18 and resistant to newer cephalosporins by the production of the extended-spectrum beta-lactamase SHV-2; the other, which colonized four patients, was capsular non-typeable and did not produce extended-spectrum beta-lactamase. Both strains were probably brought into the unit by carrier patients; the probable carrier of the non-typeable strain was transferred from another hospital but was negative on a single admission screen; the probable carrier of the K18 strain was not screened on admission because he had been born at St Thomas', but his mother had been transferred from another hospital. Despite intensive efforts to control the outbreak by standard methods of hand washing, screening, patient isolation and environmental cleaning, a total of 22 neonates on the unit eventually became colonized or infected. One of three patients with bacteraemia died. A small proportion of samples of expressed breast milk, electronic thermometers and oxygen saturation probes were contaminated by the K18 strain and may have contributed to some of the cross-infection, but this did not explain the extent of the outbreak. The outbreak was controlled only by opening a temporary ward for colonized neonates and another for newly born babies, which allowed the closure and cleaning of the main neonatal unit. Multiply antibiotic resistant klebsiellas may be highly epidemic and cause serious, difficult-to-control outbreaks on neonatal units. All patients, regardless of their admission history, should be screened on admission for carriage of multiply resistant enterobacteria by a sensitive method, and units should have plans for temporary ward closure should outbreaks occur.


Subject(s)
Cross Infection , Disease Outbreaks , Intensive Care Units, Neonatal , Klebsiella Infections , Klebsiella pneumoniae , Aminoglycosides , Anti-Bacterial Agents , Bacterial Typing Techniques , Cross Infection/epidemiology , Cross Infection/prevention & control , Disease Outbreaks/prevention & control , Drug Resistance, Microbial , Humans , Infant, Newborn , Infection Control/methods , Klebsiella Infections/epidemiology , Klebsiella Infections/prevention & control , Klebsiella pneumoniae/classification , Male
5.
Am J Clin Pathol ; 99(5): 631-6, 1993 May.
Article in English | MEDLINE | ID: mdl-8388167

ABSTRACT

An unusual presentation of anaplastic large-cell (ALC) Ki-1 lymphoma is described, in which pulmonary involvement mimicked miliary tuberculosis. Lung involvement is uncommon in this type of lymphoma, and it is not clear from previous reports whether this was a presenting feature. Bone marrow involvement, rare in Ki-1 lymphoma, also was present in this case. Despite therapy skin involvement subsequently developed, and the patient died 3 months after presentation. Postmortem examination revealed lymphomatous involvement of the heart, liver, kidneys, stomach, and lymph nodes. This case highlights the need for awareness of ALC Ki-1 lymphoma particularly when it presents at uncommon extranodal sites.


Subject(s)
Antigens, CD/analysis , Antigens, Neoplasm/analysis , Lung/pathology , Lymphoma, Large B-Cell, Diffuse/diagnosis , Tuberculosis, Miliary/diagnosis , Adult , Autopsy , Bone Marrow/pathology , Diagnosis, Differential , Female , Humans , Immunohistochemistry , Ki-1 Antigen , Kidney/pathology , Leukocyte Common Antigens/analysis , Liver/pathology , Lymph Nodes/pathology , Lymphoma, Large B-Cell, Diffuse/immunology , Lymphoma, Large B-Cell, Diffuse/pathology , Myocardium/pathology , Respiratory Distress Syndrome/diagnosis , Respiratory Distress Syndrome/pathology , Skin/chemistry , Skin/pathology , Stomach/pathology , Tuberculosis, Miliary/pathology
6.
Biochem J ; 271(3): 635-9, 1990 Nov 01.
Article in English | MEDLINE | ID: mdl-1700898

ABSTRACT

Sheep anterior-pituitary cells permeabilized with Staphylococcus aureus alpha-toxin were used to investigate the role of cyclic AMP (cAMP) in exocytosis of luteinizing hormone (lutropin, LH) under conditions where the intracellular free Ca2+ concentration ([Ca2+]free) is clamped by Ca2+ buffers. At resting [Ca2+]free (pCa 7), cAMP rapidly stimulated LH exocytosis (within 5 min) and continued to stimulate exocytosis for at least 30 min. When cAMP breakdown was inhibited by 3-isobutyl-1-methylxanthine (IBMX), the concentration giving half-maximal response (EC50) for cAMP-stimulated exocytosis was 10 microM. cAMP-stimulated exocytosis required millimolar concentrations of MgATP, as has been found with Ca2(+)- and phorbol-ester-stimulated LH exocytosis. cAMP caused a modest enhancement of Ca2(+)-stimulated LH exocytosis by decreasing in the EC50 for Ca2+ from pCa 5.6 to pCa 5.9, but had little effect on the maximal LH response to Ca2+. Activation of protein kinase C (PKC) with phorbol 12-myristate 13-acetate (PMA) dramatically enhanced cAMP-stimulated LH exocytosis by both increasing the maximal effect 5-7-fold and decreasing the EC50 for cAMP to 3 microM. This synergism between cAMP and PMA was further augmented by increasing the [Ca2+]free. Gonadotropin-releasing hormone (gonadoliberin, GnRH) stimulated cAMP production in intact pituitary cells. Since GnRH stimulation is reported to activate PKC and increase the intracellular [Ca2+]free, our results suggest that a synergistic interaction of the cAMP, PKC and Ca2+ second-messenger systems is of importance in the mechanism of GnRH-stimulated LH exocytosis.


Subject(s)
Cyclic AMP/pharmacology , Exocytosis/drug effects , Luteinizing Hormone/metabolism , Pituitary Gland, Anterior/physiology , 1-Methyl-3-isobutylxanthine/pharmacology , Adenosine Triphosphate/physiology , Animals , Calcium/pharmacokinetics , Cell Membrane Permeability/drug effects , Cyclic AMP/biosynthesis , Cyclic AMP/physiology , Drug Synergism , Gonadotropin-Releasing Hormone/pharmacology , Intracellular Fluid/physiology , Pituitary Gland, Anterior/cytology , Protein Kinase C/pharmacokinetics , Sheep , Stimulation, Chemical , Tetradecanoylphorbol Acetate/pharmacology
7.
FEBS Lett ; 267(1): 111-3, 1990 Jul 02.
Article in English | MEDLINE | ID: mdl-2163893

ABSTRACT

In intact sheep gonadotropes, the protein kinase inhibitor, staurosporine, inhibited the stimulatory effect of phorbol 12-myristate 13-acetate (PMA) on luteinizing hormone (LH) secretion. Under the same conditions staurosporine enhanced gonadotrophin-releasing hormone (GnRH)-stimulated LH exocytosis without altering the EC50 of GnRH and without affecting basal LH exocytosis. These results suggest that PKC does not play a major role in mediating acute GnRH-stimulated LH exocytosis. Furthermore, they demonstrate that staurosporine enhances GnRH stimulus-secretion coupling. Both extracellular Ca2(+)-dependent and Ca2(+)-independent components of GnRH-stimulated LH secretion were enhanced by the drug. Staurosporine had no effect on GnRH stimulation of cAMP and inositol phosphate synthesis. In permeabilized cells staurosporine did not enhance Ca2(+)- and cAMP-stimulated LH exocytosis. Based on these results we hypothesize that staurosporine inhibits a protein kinase which is activated by GnRH and which negatively modulates GnRH stimulus-secretion coupling.


Subject(s)
Alkaloids/pharmacology , Luteinizing Hormone/metabolism , Pituitary Gland, Anterior/metabolism , Pituitary Hormone-Releasing Hormones/pharmacology , Protein Kinase Inhibitors , Animals , Cells, Cultured , Cyclic AMP/metabolism , Exocytosis/drug effects , Inositol Phosphates/metabolism , Pituitary Gland, Anterior/drug effects , Sheep , Staurosporine , Tetradecanoylphorbol Acetate/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...